Market Research Logo

Molecular Diagnostics Market Analysis By Product (Instruments, Reagents), By Test Location (Point of Care, Self Test, Central Laboratories), By Application (Oncology, Breast Cancer, Prostate Cancer , Colorectal Cancer Pharmacogenomics, Infectious Disease,

Molecular Diagnostics Market Analysis By Product (Instruments, Reagents), By Test Location (Point of Care, Self Test, Central Laboratories), By Application (Oncology, Breast Cancer, Prostate Cancer , Colorectal Cancer Pharmacogenomics, Infectious Disease, MRSA, Clostridium Difficile, Vancomycin-resistant Enterococci, Carbapenem-resistant Bacteria Testing, Flu, Respiratory Syncytial Virus (RSV), Candida, Tuberculosis and drug-resistant TB), By Technology And Segment Forecasts To 2022

The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth. Moreover, increasing demand for rapid and accurate diagnostic devices for early validation of such diseases is further expected to enhance usage rates during the forecast period.

Increasing adoption of sedentary lifestyle coupled with decrease in immunity levels is expected to provide the market with a largetarget patient base. Growing awareness levels pertaining to prenatal genetic testing for early detection of developmental abnormalities and defects is also anticipated to increase penetration levels. Technological advancement on the grounds of accuracy, portability, and cost-effectiveness isalso expected to serve this market as a high impact rendering driver.

Further key findings from the report suggest:

Reagents dominated the overall market with a revenue share of over50.0% in 2014 owing to, their high usage rates. Growing initiatives by researchers in this field for detection of disease related novel biomarkers for drug development purpose isa key factor attributing for the segment's large share.

Instruments on the other hand are expected to grow at constant CAGR of 6.2% from 2015 to 2022 owing to technological advancements and rising need for lab automation.

Central laboratories dominated the overall market in terms of revenue share in 2014. Presence of established healthcare infrastructure and trained manpower are key factors attributing to its large market share.

Increasing demand for user-friendly, portable, and rapid analysis devices is a key factor resulting in the lucrative growth of the point of care devices segment. The segment is estimated to grow at a CAGR of 11.8% over the forecast period.

Infectious diseases dominated the market with share of over 50.0% in 2014 owing to the presence of high usage rates of molecular testing tools such as multiplex PCR in the detection of a myriad of infectious diseases caused by virus, bacteria, and pathogens. Commonly diagnosed infectious diseases include Clostridium difficile infection,Flu, HIV-1, HIV-2 (HIV-AIDS), HSV-1, HSV-2 (meningitis and encephalitis), Hepatitis C and B, gastro intestinal diseases, and MRSA infection.

The molecular diagnostics based oncology market is likely to witness lucrative growth over the forecast period. Increasing application of molecular diagnostic devices in the validation and differentiation of various cancer subtypes and the development of companion diagnostics for cancer drugs are further expected to boostsegment growth.

In 2014, the polymerase chain reaction technology based molecular diagnostics marketaccounted forthe largest revenue share owing to, the introduction of technologically advanced product range and higher acceptance levels by researchers

North America dominated the market in terms of revenue in 2014, owing to the presence of sophisticated healthcare infrastructure, high patient awareness levels, high levels of disposable income, and high R&D activities pertaining to drug discovery and development

Asia Pacific is expected to witness significant growth of over 12% over the forecast period. Growing base of target disease population, increasing demand for rapid diagnostic techniques for prevention of epidemics, and significant economic growth are expected to provide market with potential platform for growth

Some key players of this market include Abbott Laboratories, Alere Inc., Bayer Healthcare, Becton Dickinson, bioMerieux, Bio-Rad Laboratories, Cepheid, Dako, Danaher Corporation, Hologic(Gen Probe), Johnson & Johnson, Novartis (Grifols), Qiagen N.V., Roche Diagnostics, Siemens Healthcare, and Sysmex Corporation

Participants are constantly engaged in the introduction of technological advancements and the development of novel diagnostic products and applications in an attempt to improve marketpresence and ensure sustainability


Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sourcess
Chapter 2 Executive Summary
Chapter 3 Molecular Diagnostics – Industry Outlook
3.1 Introduction
3.2 Market Segmentation
3.3 Market Size and Growth Prospects
3.4 Molecular Diagnostics – Market dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Growing geriatric population base
3.4.1.2 Introduction of technological advancements
3.4.1.3 Increasing demand for point of care facilities
3.4.1.4 Growing prevalence of target diseases such as hospital acquired infections, genetic, cardiovascular and neurological diseases
3.4.1.5 External funding for executing research and development exercises
3.4.2 Market Restraint Analysis
3.4.2.1 Presence of ambiguous regulatory framework
3.4.2.2 High prices of molecular diagnostics tests
3.5 Key Opportunities Prioritized
3.7 Molecular Diagnostics – PESTEL Analysis
3.8 Molecular Diagnostics Market - Company Market Share Analysis, 2013
3.8.1 Recommendations for market participants
Chapter 4 Molecular Diagnostics Product Outlook
4.1 Molecular Diagnostics Revenue Share by Product, 2014 & 2022
4.2 Molecular Diagnostic Instruments Market
4.2.1 Molecular Diagnostic Instruments Market, 2012 – 2022 (USD Million)
4.3 Molecular Diagnostic Reagents Market
4.3.1 Molecular Diagnostic Reagents Market, 2012 – 2022 (USD Million)
4.4 Others
4.4.1 Other Molecular Diagnostic Products Market, 2012 – 2022 (USD Million)
Chapter 5 Molecular Diagnostics Test Location Outlook
5.1 Molecular Diagnostics Revenue Share by Test Location, 2014 & 2022
5.2 Molecular Diagnostic Point of Care Market
5.2.1 Molecular Diagnostic Point Of Care Market, 2012 – 2022 (USD Million)
5.3 Molecular Diagnostics Self-Test or OTC Market
5.3.1 Self-Test or OTC Molecular Diagnostics Market, 2012 – 2022 (USD Million)
5.4 Molecular Diagnostic Central Laboratories Market
5.4.1 Molecular Diagnostic Central Laboratories Market, 2012 – 2022 (USD Million)
Chapter 6 Molecular Diagnostics Application Outlook
6.1 Molecular Diagnostics Revenue Share by Application, 2014 & 2022
6.2 Molecular Diagnostics Based Oncology Market
6.2.1 Molecular Diagnostics Based Oncology Market, 2012 – 2022 (USD Million)
6.2.2 Molecular Diagnostics Based Breast Cancer Market, 2012 – 2022 (USD Million)
6.2.3 Molecular Diagnostics Based Prostate Cancer Market, 2012 – 2022 (USD Million)
6.2.4 Molecular Diagnostics Based Colorectal Cancer Market, 2012 – 2022 (USD Million)
6.2.5 Molecular Diagnostics Based Others Market, 2012 – 2022 (USD Million)
6.3 Molecular Diagnostics Based Pharmacogenomics Market
6.3.1 Molecular Diagnostics Based Pharmacogenomics Market, 2012 – 2022 (USD Million)
6.4 Molecular Diagnostics Based Infectious Disease Market
6.4.1 Molecular Diagnostics Based Infectious Disease Market, 2012 – 2022 (USD Million)
6.4.2 Molecular Diagnostics Based MRSA Market, 2012 – 2022 (USD Million)
6.4.3 Molecular Diagnostics Based Clostridium Difficile Market, 2012 – 2022 (USD Million)
6.4.4 Molecular Diagnostics Based Vancomycin Resistant Enterococci Market, 2012 – 2022 (USD Million)
6.4.5 Molecular Diagnostics Based Carbapenem Resistant Bacteria Testing Market, 2012 – 2022 (USD Million)
6.4.6 Molecular Diagnostics Based Flu Market, 2012 – 2022 (USD Million)
6.4.7 Molecular Diagnostics Based Respiratory Syncytial Virus Market, 2012 – 2022 (USD Million)
6.4.8 Molecular Diagnostics Based Candida Market, 2012 – 2022 (USD Million)
6.4.9 Molecular Diagnostics Based Tuberculosis and Drug Resistant TB Market, 2012 – 2022 (USD Million)
6.4.10 Molecular Diagnostics Based Meningitis Market, 2012 – 2022 (USD Million)
6.4.11 Molecular Diagnostics Based Gastro-intestinal Panel Testing Market, 2012 – 2022 (USD Million)
6.4.12 Molecular Diagnostics Based Chlamydia Market, 2012 – 2022 (USD Million)
6.4.13 Molecular Diagnostics Based Gonorrhea Market, 2012 – 2022 (USD Million)
6.4.14 Molecular Diagnostics Based HIV Market, 2012 – 2022 (USD Million)
6.4.15 Molecular Diagnostics Based Hepatitis C Market, 2012 – 2022 (USD Million)
6.4.16 Molecular Diagnostics Based Hepatitis B Market, 2012 – 2022 (USD Million)
6.4.17 Molecular Diagnostics Based Other Infectious Disease Market, 2012 – 2022 (USD Million)
6.5 Molecular Diagnostic Based Genetic Testing Market
6.5.1 Molecular Diagnostics Based Genetic Testing Market, 2012 – 2022 (USD Million)
6.5.2 Molecular Diagnostics Based Newborn Screening Market, 2012 – 2022 (USD Million)
6.5.3 Molecular Diagnostics Based Predictive and PresymptomaticTesting Market, 2012 – 2022 (USD Million)
6.5.4 Molecular Diagnostics Based Others Market, 2012 – 2022 (USD Million)
6.6 Molecular Diagnostics Based Neurological Diseases Market
6.6.1 Molecular Diagnostics Based Neurological Diseases Market, 2012 – 2022 (USD Million)
6.7 Molecular Diagnostics Based Cardiovascular Diseases Market
6.7.1 Molecular Diagnostics Based Cardiovascular Diseases Market, 2012 – 2022 (USD Million)
6.8 Molecular Diagnostics Based Food Safety Market
6.8.1 Molecular Diagnostics Based Food Safety Market, 2012 – 2022 (USD Million)
6.9 Molecular Diagnostics Based Microbiology Market
6.9.1 Molecular Diagnostics Based Microbiology Market, 2012 – 2022 (USD Million)
6.10 Molecular Diagnostics in Other Applications Market
6.10.1 Molecular Diagnostics in Other Applications, 2012 – 2022 (USD Million)
Chapter 7 Molecular Diagnostics Technology Outlook
7.1 Molecular Diagnostics Revenue Share by Technology, 2014 & 2022
7.2 Molecular Diagnostics Polymerase Chain Reaction (PCR) Market
7.2.1 Molecular Diagnostics PCR Market, 2012 – 2022 (USD Million)
7.2.2 Multiplex Polymerase Chain Reaction Based Molecular Diagnostics Market, 2012 – 2022 (USD Million)
7.2.3 Other Polymerase Chain Reaction Based Molecular Diagnostics Market, 2012 – 2022 (USD Million)
7.3 Molecular Diagnostics In-situ Hybridization Market
7.3.1 Molecular Diagnostic In-situ Hybridization Market, 2012 – 2022 (USD Million)
7.4 Molecular Diagnostics Chips and Microarrays Market
7.4.1 Molecular Diagnostics Chips and Microarrays Market, 2012 – 2022 (USD Million)
7.5 Molecular Diagnostics Mass Spectrometry (MS) Market
7.5.1 Molecular Diagnostics Mass Spectrometry Market, 2012 – 2022 (USD Million)
7.6 Molecular Diagnostic Sequencing Market
7.6.1 Molecular Diagnostic Sequencing Market, 2012 – 2022 (USD Million)
7.7 Molecular Diagnostics Transcription Mediated Amplification (TMA) Market
7.7.1 Molecular Diagnostics TMA Market, 2012 – 2022 (USD Million)
7.8 Molecular Diagnostic Other Technology Segments Market
7.8.1 Molecular Diagnostic Other Technology Segments Market, 2012 – 2022 (USD Million)
Chapter 8 Molecular Diagnostics Regional Outlook
8.1 Molecular Diagnostics Revenue Share by Region, 2014 & 2022
8.2 North America
8.2.1 North America Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.2.2 U.S. Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.2.3 Canada Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3 Europe
8.3.1 Europe Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3.2 UK Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3.3 Germany Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3.4 France Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3.5 Spain Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.3.6 Italy Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4.2 Japan Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4.3 China Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4.4 India Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4.5 Australia Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.4.6 New Zealand Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.5 Latin America
8.5.1 Latin America Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.5.2 Brazil Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.5.3 Mexico Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.5.4 Colombia Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.6 MEA
8.6.1 MEA Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.6.2 South Africa Molecular Diagnostic Market, 2012 – 2022 (USD Million)
8.6.3 Saudi Arabia Molecular Diagnostic Market, 2012 – 2022 (USD Million)
Chapter 9 Competitive Landscape
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Performance
9.1.3 Product Benchmarking
9.1.4 Strategic Initiatives
9.2 Alere Inc.
9.2.1 Company Overview
9.2.2 Financial Performance
9.2.3 Product Benchmarking
9.2.4 Strategic Initiatives
9.3 Bayer Healthcare
9.3.1 Company Overview
9.3.2 Financial Performance
9.3.3 Product Benchmarking
9.3.4 Strategic Initiatives
9.4 Becton Dickinson
9.4.1 Company Overview
9.4.2 Financial Performance
9.4.3 Product Benchmarking
9.4.4 Strategic Initiatives
9.5 bioMerieux
9.5.1 Company Overview
9.5.2 Financial Performance
9.5.3 Product Benchmarking
9.5.4 Strategic Initiatives
9.6 Bio-Rad Laboratories ‏
9.6.1 Company Overview
9.6.2 Financial Performance
9.6.3 Product Benchmarking
9.6.4 Strategic Initiatives
9.7 Cepheid
9.7.1 Company Overview
9.7.2 Financial Performance
9.7.3 Product Benchmarking
9.7.4 Strategic Initiatives
9.8 Dako
9.8.1 Company Overview
9.8.2 Financial Performance
9.8.3 Product Benchmarking
9.8.4 Strategic Initiatives
9.9 Danaher Corporation
9.9.1 Company Overview
9.9.2 Financial Performance
9.9.3 Product Benchmarking
9.9.4 Strategic Initiatives of Danaher Corporation
9.10 Hologic (Gen Probe)
9.10.1 Company Overview
9.10.2 Financial Performance
9.10.3 Product Benchmarking
9.11 Johnson & Johnson
9.11.1 Company Overview
9.11.2 Financial Performance
9.11.3 Product Benchmarking
9.11.4 Strategic Initiatives
9.12 Novartis (Grifols)
9.12.1 Company Overview
9.12.2 Financial Performance
9.12.3 Product Benchmarking
9.12.4 Strategic Initiatives
9.13 Qiagen N.V.
9.13.1 Company Overview
9.13.2 Financial Performance
9.13.3 Product Benchmarking
9.13.4 Strategic Initiatives
9.14 Roche Diagnostics
9.14.1 Company Overview
9.14.2 Financial Performance
9.14.3 Product Benchmarking
9.14.4 Strategic Initiatives
9.15 Siemens Healthcare
9.15.1 Company Overview
9.15.2 Financial Performance
9.15.3 Product Benchmarking
9.15.4 Strategic Initiatives
9.16 Sysmex Corporation
9.16.1 Company Overview
9.16.2 Financial Performance
9.16.3 Product Benchmarking
9.16.4 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report